Salman Hussain is a panelist during the conference. He is discussing patient-focused drug development, bringing a precision medicine approach to alopecia areata, and the latest patient reported outcomes tools and biomarker studies. The roundtable discussion includes representatives from several pharmaceutical companies, a couple physicians/researchers, and patient advocacy group members.
For more inforamtion on this event, click here.
An analysis of the effect of drug pricing provisions in the Build Back Better Act on pharmaceutical innovation
Charles River Associates has previously assessed the implications of proposals to implement international reference pricing in the US and found they would...